|
pubmed:abstractText |
The dependence of tumor growth and metastasis on blood vessels makes tumor angiogenesis a rational target for cancer therapy. One of the key mediators of angiogenesis is vascular endothelial growth factor (VEGF), which is an appealing target for anticancer therapy. The development of anti-VEGF/VEGFR agents and the latest clinical data are reviewed, including bevacizumab as a monoclonal antibody to VEGF, sunitinib and sorafenib as VEGFR tyrosine kinase inhibitors, and IMC-1C11 as VEGFR monoclonal antibody.
|
|
pubmed:affiliation |
Department of Medical Oncology, Cancer Hospital, Fudan University, Shanghai, 200032, PR China. 0256277@fudan.edu.cn
|
